GlassScriptPhysician profile
James Ndungu
NPI 1144570342
$4,127.17
in general payments reported to CMS, 2019-2025
15 companies · $1,520 in 2025
The $1,520 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $188 · 2022: $133 · 2023: $295 · 2024: $1,991 · 2025: $1,520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,679 · Travel and Lodging: $921 · Education: $207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,678.88 |
| Travel and Lodging | $920.79 |
| Education | $206.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,381.74 | 2023-2025 | Spravato |
| Alkermes, INC. | $540.11 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Braeburn INC. | $485.61 | 2023-2025 | Brixadi |
| Teva Pharmaceuticals USA, INC. | $438.09 | 2024-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $291.05 | 2023-2025 | Qelbree, Qelbree |
| Indivior INC. | $282.82 | 2021-2025 | Sublocade, Perseris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $232.32 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $226.30 | 2022-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Axsome Therapeutics, INC. | $59.67 | 2024-2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.60 | 2023-2024 | Trulance, Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $47.76 | 2025 | Cobenfy |
| Astellas Pharma US INC | $27.55 | 2025 | Veozah |
| Amgen INC. | $22.87 | 2021 | |
| Almatica Pharma LLC | $21.27 | 2022 | |
| Lundbeck LLC | $12.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ndungu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.